検索ワード: fpg (英語 - デンマーク語)

self­measured fpg
egen fpg-måling

mean fpg at gw 36 (mmol/l)
middel-fpg ved gw 36 (mmol/l)

fasting plasma glucose (fpg) (mmol/l)
fasteplasmaglucose (fpg) (mmol/l)

fpg/hba1c monitoring during treatment should follow established guidelines.
fpg/hba1c-monitorering under behandlingen skal følge etablerede retningslinjer.

furthermore, empagliflozin resulted in a reduction in fpg, body weight and blood pressure.
endvidere medførte empagliflozin et fald i fpg, legemsvægt og blodtryk.

furthermore, empagliflozin resulted in a reduction in fpg, body weight, and blood pressure.
desuden medførte empagliflozin et fald i fpg, kropsvægt og blodtryk.

improvements in hba1c, ppg and fpg following initial therapy with saxagliptin 5 mg plus metformin were sustained up to week 76.
forbedringerne i hba1c, ppg og fpg efter initial behandling med saxagliptin 5 mg + metformin blev opretholdt frem til uge 76.

improvements in hba1c, ppg, and fpg following initial therapy with saxagliptin 5 mg plus metformin were sustained up to week 76.
forbedringerne i hba1c, ppg og fpg efter initialbehandling med saxagliptin 5 mg plus metformin holdt sig frem til uge 76.

at week 52, treatment with empagliflozin resulted in a statistically significant decrease in hba1c and insulin sparing compared with placebo and a reduction in fpg and body weight.
ved uge 52 gav behandling med empagliflozin en statistisk signifikant reduktion i hba1c og insulinbesparelse sammenlignet med placebo samt en reduktion i fpg og kropsvægt.

the reduction in fpg was slightly less in the saxagliptin group and there were more discontinuations (3.5% vs.
reduktionen i fpg var lidt mindre i saxagliptingruppen, og der var flere ophør (3,5 % vs.

in addition, the reductions in hba1c and fpg with sitagliptin compared to placebo were generally similar to those observed in other monotherapy studies in patients with normal renal function (see section 5.2).
desuden var reduktionerne i hba1c og fpg for sitagliptin, sammenlignet med placebo, generelt de samme som dem, der er observeret i andre monoterapiundersøgelser hos patienter med normal nyrefunktion (se afsnit 5. 2).